The International Neuromodulation SocietyThe Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of NeuromodulationThe International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field. Donate TodayThe INS Peer-Reviewed JournalThe INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.
The Neuromodulation Podcast has been developed for our membership to dive into the forefront of today's emerging neuromodulation techniques, insights, and ethical and clinical applications. Join the multidisciplinary collaboration of medical care providers, scientists, and engineers who are part of the global conversation that's shaping the future of healthcare. Subscribe now wherever you get your podcasts. What is Neuromodulation?Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application. Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:
Breaking NewsFDA Clears Non-Invasive Neurostimulation Device for Weight Management December 11, 2025 - U.S. regulators have granted de novo approval to a non-invasive neurostimulation device intended for weight management, which delivers low-level electrical stimulation to brain regions involved in metabolic regulation. In a clinical trial of overweight and obese adults, use of the device was associated with a clinically meaningful reduction in visceral fat over six months while preserving lean muscle mass. The approval allows the device to be prescribed in the U.S., with further studies planned for other conditions. (Source: Mass Device) FDA Аpproves At-Home Neurostimulation for Depression December 11, 2025 - The U.S. Food and Drug Administration has approved a non-invasive, at-home neurostimulation system for the treatment of major depressive disorder in adults. The device uses transcranial direct current stimulation to target brain regions involved in mood regulation and can be prescribed as a standalone or adjunctive therapy. Clinical studies have shown symptom improvement within weeks, with generally mild and transient side effects. (Source: Mass Device) Brain-Computer Interface Boosts Recovery in Stroke Patients with Upper Limb Paralysis November 12, 2025 - A new study found that combining brain-computer interface (BCI) training with standard rehabilitation significantly improved upper limb function and daily living abilities in ischemic stroke patients compared to conventional therapy alone. Using functional near-infrared spectroscopy (fNIRS), researchers observed increased activation in key motor cortex areas and enhanced brain network efficiency after four weeks of BCI-assisted therapy. (Source: Scientific Reports) FDA Approves Non-Invasive Magnetic Stimulation Therapy for Chronic Pain November 12, 2025 - The U.S. Food and Drug Administration has approved a non-invasive magnetic stimulation therapy for the treatment of chronic pain, offering a drug-free alternative that targets neural pathways involved in pain processing. Clinical studies have shown that the therapy can reduce pain intensity and improve physical function and quality of life. The clearance marks a significant step toward expanding evidence-based, non-addictive pain management options for patients and healthcare providers. (Source: Yahoo Finance) Brain-Computer Interface Successfully Decodes Mandarin Speech November 6, 2025 - Researchers have developed a brain-computer interface capable of decoding Mandarin speech in real time using high-density cortical recordings. The findings highlight the potential for advanced BCIs to restore communication and motor function for people with speech or movement impairments while stressing the need for broader studies to improve accuracy and generalizability. (Source: Medical Xpress) To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive. Continue Reading News Briefs |
